Is NAD+ Therapy Legit? What It Actually Does — and What It Doesn’t
NAD+ is marketed with unusual confidence for a product this thinly studied. Websites promise energy, focus, recovery and healthy aging, often on the same page. The underlying biochemistry is real and well established. The human trial evidence, however, is narrower than the marketing implies, and most of it studies a different product from the one being sold. Here is what holds up, what does not, and what to ask before you pay.
Key Takeaways
| Claim | Where it stands |
|---|---|
| NAD+ is essential to cellular energy metabolism | Established biochemistry, not in dispute |
| Supplementing a precursor raises blood NAD+ | Shown in a 140 person randomized trial, dose dependently |
| Raising NAD+ produces the advertised benefits | Not established by the trial that measured the increase |
| Injected and nasal NAD+ work like the studied oral precursors | Different route, different product, far thinner human evidence |
| Any program publishes its own outcome data | None of the six we checked |
What NAD+ Actually Is
NAD+ is a coenzyme present in every cell in your body. It carries electrons in the reactions that turn food into usable energy, and it is a required substrate for several families of repair enzymes. None of that is controversial, and you will find it in any biochemistry textbook.
The marketing leap happens at the next step. Because NAD+ matters to energy metabolism, sellers reason that more of it should mean more energy. That reasoning is plausible. It is not the same as evidence, and the distinction is the whole subject of this article.
What the Human Trials Have Shown
The clearest human result comes from a randomized, double blind, placebo controlled trial of nicotinamide riboside, an oral NAD+ precursor. Researchers enrolled 140 healthy overweight adults aged 40 to 60 and ran three doses against placebo for eight weeks. Whole blood NAD+ rose dose dependently: about 22 percent at 100mg a day, 51 percent at 300mg, and 142 percent at 1000mg, measured at day 14 and largely sustained to day 56.
Safety looked reassuring. The authors reported no significant difference in adverse events against placebo, no flushing, no rise in LDL cholesterol and no meaningful hematological changes. Their stated conclusion was measured, and worth reading literally: the data support developing a tolerable upper intake limit for the compound based on human data. You can read the full trial in PubMed Central.
Read that carefully and notice what it does not say. The trial demonstrated that a precursor raises NAD+ and appears well tolerated. It did not demonstrate more energy, sharper focus, better recovery or slower aging. Those are the claims doing the selling, and this study was not designed to test them.
The Gap Between the Research and the Product
Here is the part most buyer guides skip. The bulk of the human research on raising NAD+ uses oral precursors such as nicotinamide riboside and nicotinamide mononucleotide. The telehealth market sells something else: NAD+ itself, delivered by subcutaneous injection or nasal spray.
Those are different molecules taking different routes into the body. Evidence that an oral precursor raises blood NAD+ over eight weeks does not automatically transfer to an injected or intranasal product. It might behave similarly. It might not. We did not find head to head human trials comparing these routes, and no seller we checked cited any.
Sellers do make route specific claims. Telos Rx describes intranasal delivery as bypassing the digestive tract for absorption through the nasal mucosa. Lttl describes injection as offering 100 percent bioavailability. Those are the companies’ assertions about their own products, and neither is presented with a citation. Treat them as advertising rather than findings.
What the Sellers Do and Do Not Disclose
We checked six NAD+ telehealth programs on August 16, 2026. Not one publishes outcome data on its own patients. Not one bills insurance. Every one dispenses a compounded medication, which means a licensed pharmacy prepares it but the finished product is not FDA approved.
Several companies are direct about the limits. Telos Rx states on its own site that compounded medications are not FDA approved and that prescriptions are never automatic. Care Bare Rx states that it is a technology platform rather than a medical provider, and that payment does not guarantee a prescription. That candour is worth something when you are comparing programs.
Others lean harder on language that outruns the evidence. Phrases about reversing the clock or restoring youth appear across the category. When a company writes that way, the claim is doing marketing work rather than clinical work, and you should discount it accordingly.
So Is It Legitimate?
Legitimate is two questions wearing one word. Are these real companies dispensing real medication through licensed channels? For the programs we checked, largely yes. They carry LegitScript certification, they name compounding pharmacies, they route prescriptions through licensed clinicians, and they publish prices you can read without an intake.
Will it do what the landing page implies? That is unproven for the injected and nasal products being sold. The strongest human data covers oral precursors, shows the intended biochemical effect, and stops short of the outcomes people are buying. Anyone telling you otherwise is ahead of the published record.
A reasonable way to hold both facts at once: this is a legitimate market selling a plausible intervention with incomplete evidence, at a price that ranges from $119 to $249 a month. If that trade appeals to you, the sensible move is to pay the least you can while you find out. Our ranked comparison of NAD+ programs by monthly price exists for exactly that.
Questions Worth Asking First
Does NAD+ therapy have FDA approval?
No. These are compounded medications prepared by licensed pharmacies, and compounded products are not FDA approved. Several sellers state this on their own sites.
Is it safe?
The eight week trial of oral nicotinamide riboside found adverse events comparable to placebo at doses up to 1000mg a day. That is a finding about one oral precursor over two months, not a general safety verdict on injected or nasal NAD+. Ask a clinician who knows your history.
Why do clinics charge so much more?
Because they bill per infusion rather than per month, and the visit includes supervised administration. Our NAD+ cost breakdown compares the two models with published figures.
What should I ask a provider?
Ask which molecule you are actually receiving, at what dose, by what route, and what evidence they rely on for that specific combination. Ask what happens if it does nothing after three months. Ask about the refund policy, since most programs do not publish one.
This article is for informational purposes and is not medical advice. Compounded medications are not FDA approved. Talk to a qualified provider before starting, stopping, or changing any treatment.
